API | odalasvir

odalasvir Report issue

Small molecule Experimental

AACT ChEMBL DrugBank PubChem

Active Ingredient History

NOW

Odalasvir is an investigational new drug in development for the treatment of hepatitis C. It is an NS5A inhibitor. The NS5A protein serves multiple functions at various stages of the viral life cycle, including viral replication. NS5A also plays a role in the development of interferon-resistance, a common cause of treatment failure. It is under development by Achillion Pharmaceuticals. ^Wikipedia

Chemistry

SMILES: COC(=O)N[C@H](C(=O)N1[C@H](c2nc3cc(-c4cc5ccc4CCc4ccc(c(-c6ccc7[nH]c([C@@H]8C[C@@H]9CCCC[C@@H]9N8C(=O)[C@@H](NC(=O)OC)C(C)C)nc7c6)c4)CC5)ccc3[nH]2)C[C@@H]2CCCC[C@@H]21)C(C)C
InChIKey: LSYBRGMTRKJATA-IVEWBXRVSA-N
Mol. Mass: 1001.29
ALogP: Missing data
ChEMBL Molecule:
odalasvir

More Chemistry

Pharmacology

Mechanisms of Action:
- Genome polyprotein (Hepatitis C virus genotype 1b (strain HC-J4) (HCV)) ^UniProt
- Nonstructural protein 5A (Hepatitis C virus) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

ach-0143102 | ach-3102 | odalasvir

Organizations (4)

Research & Development (4)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (4)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (4)

Healthy Volunteers (Phase 1)

Hepatitis C, Chronic (Phase 2)

Liver Diseases (Phase 1)

Renal Insufficiency (Phase 1)

Overview

Highest Phase: Phase 2
# of Trials: 15
# of Trial Organizations: 4

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue